NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

ORIC Pharmaceuticals, Inc. (ORIC) Stock Analysis

ORIC Pharmaceuticals, Inc. (ORIC) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ORIC

$13.85

+$0.07 (+0.51%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ORIC with… →

ORIC Key Statistics

As of Oct 21, 2026
Trading
Open
$13.81
Previous Close
$13.78
Day's Range
13.74–14.20
52-Week Range
7.23–14.68
Volume
1.57M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.98
Valuation
Market Cap
$1.44B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.32
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$129.47M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
103.65M
1-Year Return
+9.92%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
1.49M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ORIC closed at $13.85, +9.92% over 1 year.

ORIC Pharmaceuticals, Inc. (ORIC) has a market capitalization of $1.44B.

In fiscal 2025, ORIC reported revenue of $0.00.

ORIC Stock Return by Calendar Year

ORIC Pharmaceuticals, Inc. (ORIC) return since Apr 2020: what $10,000 became

1 year
$10,000 $10,992
+9.92%
5 years
$10,000 $9,166
−8.34%
Since Apr 2020
$10,000 $5,374
−46.26%

If you had invested $10,000 in ORIC Pharmaceuticals, Inc. (ORIC) at the close on April 24, 2020, the earliest close on record here, it would have been worth $5,374 at the close on October 21, 2026: −46.26% in total, −9.12% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+69.32%
2025+1.36%
2024−12.28%
2023+56.20%
2022−59.93%
2021−56.57%
2020 (partial year)+31.35%

As of October 21, 2026.

ORIC Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$129.47M—
2024$0.00−$127.85M—
2023$0.00−$100.70M—
2022$0.00−$89.12M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$143.00M−$129.47M—
2024$0.00—−$142.90M−$127.85M—
2023$0.00—−$110.78M−$100.70M—
2022$0.00—−$86.77M−$89.12M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

ORIC Pharmaceuticals, Inc. (ORIC) is capitalised at $1.44B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 111 employees.

The most recent close on file for ORIC is $13.85, dated October 21, 2026. That is +$0.07 (+0.51%) against the previous close. The 52-week range on file runs from $7.23 to $14.68. The latest close sits 91.56% above that 52-week low.

Financial Health

In fiscal 2025, ORIC Pharmaceuticals, Inc. reported revenue of $0.00. The same year closed with a net loss of $129.47M. Trailing earnings per share are −1.32.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year total return is +9.92%. Measured over 5 years, that is −1.73% a year compounded. The reported beta is 0.98. Daily returns over the trailing 6 years annualize to a volatility of 87.47%.

Growth & Income

No dividend is on file for ORIC.

2026 is still running; the total return is +69.32% year to date. Across the complete calendar years on file, 2023 returned +56.20% and 2022 returned −59.93%. Of the 5 complete calendar years on file, 2 finished higher.

Peer Comparison

ORIC Pharmaceuticals, Inc. (ORIC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
ORIC Pharmaceuticals, Inc. ORIC $1.44B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. ORIC Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Visit website →